Irinotecan/capecitabine versus cisplatin/capecitabine in advanced adenocarcinoma of the stomach or gastroesophageal junction: Interimsanalysis of a german AIO phase II study

被引：0
|
作者：
Moehler, M.
Kanzler, S.
Geissler, M.
Raedle, J.
Ebert, M.
Scherubl, H.
Flieger, D.
Seufferlein, T.
Galle, P. R.
Hoehler, T.
机构：
[1] Univ Mainz, Dept Med 1, D-6500 Mainz, Germany
[2] Univ Freiburg, Dept Med, D-7800 Freiburg, Germany
[3] Univ Homburg, Dept Med, D-6650 Homburg, Germany
[4] Univ Magdeburg, Dept Med, D-39106 Magdeburg, Germany
[5] Dept Med, Berlin, Germany
[6] Klinikum Aschaffenburg, Dept Med, Aschaffenburg, Germany
[7] Univ Ulm, Dept Med, D-89069 Ulm, Germany
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：313 / 313
页数：1
相关论文
共 50 条
  • [21] Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
    Ocean, Allyson J.
    Christos, Paul
    Sparano, Joseph A.
    Shah, Manish A.
    Yantiss, Rhonda K.
    Cheng, Jonathan
    Lin, Juan
    Papetti, Michael
    Matulich, Dan
    Schnoll-Sussman, Felice
    Besanceney-Webler, Christen
    Xiang, Jenny
    Ward, Maureen
    Dilts, Kaili Temple
    Keresztes, Roger
    Holloway, Shannon
    Chen, Eric X.
    Wright, John J.
    Lane, Maureen E.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (03) : 542 - 548
  • [22] Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach
    Allyson J. Ocean
    Paul Christos
    Joseph A. Sparano
    Manish A. Shah
    Rhonda K. Yantiss
    Jonathan Cheng
    Juan Lin
    Michael Papetti
    Dan Matulich
    Felice Schnoll-Sussman
    Christen Besanceney-Webler
    Jenny Xiang
    Maureen Ward
    Kaili Temple Dilts
    Roger Keresztes
    Shannon Holloway
    Eric X. Chen
    John J. Wright
    Maureen E. Lane
    Investigational New Drugs, 2014, 32 : 542 - 548
  • [23] Activity of the combination of bevacizumab (Bev) with capecitabine/irinotecan (CapIri/Bev) or capecitabine/oxaliplatin (CapOx/Bev) in advanced colorectal cancer (ACRC): A randomized phase II study of the AIO Colorectal Study Group (AIO trial 0604)
    Reinacher-Schick, A. C.
    Kubicka, S.
    Freier, W.
    Arnold, D.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Graeven, U.
    Schmoll, H.
    Schmiegel, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] A phase II study of capecitabine-oxaliplatin and cetuximab in patients (pts) with advanced/metastatic gastric cancer (G) or gastroesophageal junction (GEJ) adenocarcinoma
    Iqbal, Syma
    El-Khoueiry, Anthony B.
    Yang, Dongyun
    Paez, David
    Duddalwar, Vinay
    Zhang, Wu
    Agafitei, Raluca Dana
    Lujan, Ramona
    Cole, Sarah
    Ning, Yan
    El-Khoueiry, Rita
    Loupakis, Fotios
    Wakatsuki, Takeru
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] Comparable safety and response rate with bevacizumab in combination with capecitabine/oxaliplatin (CapOx/Bev) versus capecitabine/irinotecan (CapIri/Bev) in advanced CRC (mCRC): A randomized phase II study of the AIO GI tumor study group
    Schmiegel, W. H.
    Reinacher-Schick, A.
    Freier, W.
    Dietrich, G.
    Arnold, D.
    Kanzler, S.
    Geissler, M.
    Graeven, U.
    Hegewisch-Becker, S.
    Schmoll, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [26] A phase II study of oxaliplatin, docetaxel, and capecitabine in advanced carcinoma of the esophagus and stomach
    Anderson, E. J.
    Safran, H.
    Miner, T.
    Shipley, J.
    Mcnulty, B.
    Akerman, P.
    Saba, N.
    Jean, M.
    Millis, R.
    Sio, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] RTOG 0247: A randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer
    Wong, S. J.
    Winter, K.
    Meropol, N. J.
    Anne, R.
    Kachnic, L. A.
    Rashid, A.
    Watson, J. C.
    Mitchell, E. P.
    Pollock, J.
    Lee, R. J.
    Willett, C. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)†
    Thuss-Patience, P. C.
    Hofheinz, R. D.
    Arnold, D.
    Florschuetz, A.
    Daum, S.
    Kretzschmar, A.
    Mantovani-Loeffler, L.
    Bichev, D.
    Breithaupt, K.
    Kneba, M.
    Schumacher, G.
    Glanemann, M.
    Schlattmann, P.
    Reichardt, P.
    Gahn, B.
    ANNALS OF ONCOLOGY, 2012, 23 (11) : 2827 - 2834
  • [29] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    J H Baek
    J G Kim
    S B Jeon
    Y S Chae
    D H Kim
    S K Sohn
    K B Lee
    Y J Choi
    H J Shin
    J S Chung
    G J Cho
    H Y Jung
    W Yu
    British Journal of Cancer, 2006, 94 : 1407 - 1411
  • [30] Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
    Baek, J. H.
    Kim, J. G.
    Jeon, S. B.
    Chae, Y. S.
    Kim, D. H.
    Sohn, S. K.
    Lee, K. B.
    Choi, Y. J.
    Shin, H. J.
    Chung, J. S.
    Cho, G. J.
    Jung, H. Y.
    Yu, W.
    BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1407 - 1411
12345